Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.25p +2.53% 10.15p 9.80p 10.50p 10.15p 9.90p 9.90p 124,224 09:31:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 13.6 -6.9 -0.4 - 14

Omega Diagnostics Share Discussion Threads

Showing 3501 to 3525 of 3525 messages
Chat Pages: 141  140  139  138  137  136  135  134  133  132  131  130  Older
DateSubjectAuthorDiscuss
23/8/2019
10:10
Bomber13, great summary of the investor meeting, many thanks. The current m/cap is covered by the Food Intolerance division, as Finncap have pointed out, and this division should continue to grow nicely, leaving everything else in for free. We should soon get positive news re CD4 re ERPD approval. As the market latches on to the near-term potential from CD4 - and assuming the results are out next month as anticipated without hitches - then there's loads of upside. And even the Allergies side of the business is starting to show signs of coming to fruition. I've topped up with a few more this week.
rivaldo
22/8/2019
22:13
Spivs.it is not up to pis to promote this gemme of a company
upomega
22/8/2019
18:24
Cheers bomber, I take it you were encouraged by what you heard from the Directors..
barrywhit
22/8/2019
18:09
Hi there Barrywhit , I would say there were 20 to 25 of us at the investor evening , and my guess is that we were predominantly private investors . The PR man said they ( Colin and Kieron ) were doing 2 days of meetings in London Tuesday / Wednesday , and then a day in Scotland today , and these are probably institutional investors they were seeing . That may account for the higher volume this week , which is very encouraging .
bomber13
22/8/2019
17:46
Inmo. The biggest danger now is that some kind of bid/merger happens.I am sure that any long term holders together with long ish holders would not want this to happen. Hopefully the directors feel the same.
upomega
22/8/2019
14:04
There must be quite an overhang of stock to be cleared...good to see some buying though...
barrywhit
22/8/2019
08:27
bomber, Were there many Private Investors at the Investor Presentation Evening???
barrywhit
22/8/2019
08:22
Dream on Little orders like those announced will be IMO obviously loss making Ask the company how many CD4 sales are needed each year to break even Bet you won't get an answer
buywell3
22/8/2019
08:16
With commercialisation of CD4, this could get taken over at multiples of current share price. Major shareholders have been accumulating, with a few being activist investors.
likitorma
22/8/2019
08:08
Tick-up in the morning. Should be sitting in low 20s.
likitorma
21/8/2019
12:09
Can't understand people selling now!
leedslad001
21/8/2019
11:41
Thanks bomber.excellent post.this could end up being one of the uk fasting growing companies'.
upomega
21/8/2019
11:41
Thanks bomber.excellent post.this could end up being one of the uk fasting growing companies'.
upomega
21/8/2019
11:40
Same here filter straight away total waster
leedslad001
21/8/2019
11:34
Another Name buywell2 this one filtered as well...
barrywhit
21/8/2019
11:21
Sounds like more jam tomorrow and for the next 3 years to me And that going into the start of a US recession confirmed by DOW Theory yesterday
buywell2
21/8/2019
11:17
Yes thanks for the info sounds good
leedslad001
21/8/2019
10:55
All it adds up to is words buywell prefers actions
buywell3
21/8/2019
10:52
Many thanks bomber, a very comprehensive summary, all adds up to a very promising few years..
barrywhit
21/8/2019
09:59
I attended the investor briefing on Monday evening ,and I said that I would post my deliberations . Herewith a precis FYI . The CEO's immediate message was that nothing untoward should be read into the deferral of the final results to September . Omega is expecting ERPD approval for their manual CD4 test any day now , and certain commercial discussions are awaiting clarity . Both areas have thrown up factors outside management control , so it was thought best to give extra time for these matters to resolve . Looking at the 3 business segments , here is a concoction of what was said - ALLERGIES - Omega now have 62 allergens available on the IDS system , and is on track to to add 10 a year . The allergy panel went live on IDS in March , and some modest sales have been struck . A hockey stick effect in sales will not occur until the 80 allergen threshold is crossed within the next 2 years , a level which would enable the j/v to enter into proper contracts and tenders . IDS did a comprehensive survey of the allergy marketplace , and this threw out the need to have mixes of allergens for specific tree , nut , food , grass and pet allergies , and these areas will be the j/v’s focus . The market has high barriers to entry , and there are only 4 global players with Thermo-Fisher dominating the top end high volume segment . Omega claims to have a superior offering to Thermo-Fisher’s big machines in that their smaller footprint makes them faster , and nimbler to achieve the same results . The European market available to IDS is worth £230m pa , and Omega is targeting a £12m share within 5 years at 70% margins . FOOD INTOLERANCE - Omega’s food intolerance division returned to 7% growth in the year to March , and the CEO was at pains to say that this was achieved across the board in Europe , the Far East and North America , and that he is confident that this growth rate will accelerate into double digits this year . He also said that in many ways the biggest achievement was developing a specific food detective panel for the Chinese market , and securing its first order . This had not been expected for another 6 to 9 months . With the first order received for 20000 tests with delivery in September , a second order for 30000 tests is expected for October delivery with a possible further order being mooted . Approval for laboratory testing is expected in September and for self-testing by calendar year end , this being a much larger market . To this end Omega’s partner is developing a specific App on which to keep self-test data etc , and it is believed that the 2 other competitors in China will not get approval to launch in self-test because they do not currently have the in-house technicians . Omega believes there is potential for 0.5m tests within 18 months in China at US$15 per test . In North America , Omega is seeing renewed demand , and this is its highest margin area . With the benefit of a bespoke App , launch of Foodprint direct to the US consumer is expected to take place in January . Of the global US$130m food intolerance market ( USA US$26m / China US$20m ) , Omega is targetting US$19.5m of sales pa within 3 -5 years . VISITECT CD4 - Omega has substantially derisked their 350 and 200 cut off tests , both now CE marked , and with regulatory files submitted to the WHO and ERPD . The latter process takes 4 months , and they are 10 weeks or so into that protocol , hence the expectation of imminent approval . With the WHO , Omega has entered the final technical review stage to prove Visitect’s efficacy and safety in the field . All being well Omega would expect to attain WHO accreditation in March/April 2020 . For some specific aid agencies such as CHAI , ERPD approval would be enough to roll out the Visitect 200 advanced test in 7 countries , but for NGO’s like Unicef , who have the ability to bypass all individual country registration processes , WHO approval is needed . Feedback from all agencies still suggest that a disposable point of care CD4 test kit requiring no power is hugely advantageous . Indeed , there have been several instances of breakdowns , poor maintenance , and vulnerability to power cuts when using some of other point of care instruments . In fact one US aid agency has publicly stated that it will no longer buy instrumentation and will only buy lateral flow test kits , of which there is only one , Omega’s . The number of deaths from AIDS each year has stopped falling , and has now plateaued at 1m pa out of an AIDS population of 37m people . It is thought that one of the main reasons for this is the difficulty in easy monitoring of the advancing state of the disease . On a country by country basis , Omega are targeting 24 for distribution partners , and they currently have 18 in place . In Nigeria , the worst AIDS affected in Africa , results from a 6 state evaluation of Visitect have been very good , and approval for a nationwide roll-out is hoped for shortly , to which end CD4 testing is expected to form part of spending within a large government fund recently set up to manage HIV within Nigeria . The initial order from Nigeria just announced has payment terms of 50% upfront and 50% on delivery , and Omega’s distribution partner is very well connected at a government level . In terms of the overall global market , the WHO has estimated that 6m point of care tests pa are needed , and Omega are targeting 4m of these tests for themselves within 3 - 5 years at US$5 per test , equalling US$20m . The plant at Alva in Scotland can produce 2m -3m tests pa on a single shift basis , but it is easily scalable in terms of better labour utilisation , automation and increased space . The Burnet patent will make it very difficult for competitors for at least 10 years , and Omega has no intention of offering a discount for volume to the US$5 per test list price . All in all , I thought it was an excellent meeting , and I think these next 12 months are potentially transformational for Omega . The FD did not deny the need for additional funds , but much depends on the timing of approvals and the rate of growth . With firm orders , Omega is far more likely to draw down debt than raise equity . Indeed , the CEO said that there are no current plans to raise further equity .
bomber13
21/8/2019
09:28
Both 100k trades in past day clearly buys. Sneller beginning to add again? Happy with recent announcements. £580k of orders in the past week is not bad. Regarding the ERPD (which is a crucial milestone for larger scale orders) the company expected to submit the dossier by end April. My research tells me that the ‘time limited outcome’ for this process should take no longer than four months. On that basis we should know the outcome by the end of this month or very soon after. Hopefully the tide is turning.
dibs61
20/8/2019
15:34
INMO share price is only going to go one way and that is up. For those that have been patient I believe we are now going to start reaping the rewards...
maximillian3
20/8/2019
12:52
Directors will be on a lock out until full results are published so no Director buys soon!
maximillian3
20/8/2019
10:01
Delayed 100k purchase. Director Buy???
barrywhit
20/8/2019
08:18
Fake bid as cannot even get firm sell quote for 25k online. I guess MMs will drop bid shortly.
likitorma
Chat Pages: 141  140  139  138  137  136  135  134  133  132  131  130  Older
Your Recent History
LSE
ODX
Omega Diag..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190823 10:49:07